MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

EQS-News: MorphoSys AG


/ Key word: Miscellaneous





MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023... | April 4, 2023

Related Keywords

Boston ,Massachusetts ,United States ,Germany ,Italy ,Planegg ,Bayern ,Canada ,Lugano ,Italy General ,American ,German ,Italian ,Julia Neugebauer ,Tim Demuth ,Eamonn Nolan ,Thomas Biegi ,American Society Of Hematology ,German Lymphoma Association ,Drug Administration ,Twitter ,Constellation Pharmaceuticals Inc ,Xencor Inc ,Linkedin ,Nasdaq ,Us Oncology Network ,Exchange Commission ,Sys Completes Enrollment ,Topline Results Expected ,Chief Research ,Development Officer ,Myelofibrosis Symptom Assessment Form ,American Society ,Constellation Pharmaceuticals ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Medication Guide ,Prescribing Information ,Patient Information ,Important Safety ,Diffuse Largeb Cell Lymphoma ,Italian Lymphoma ,Blinded Independent Review Committee ,Morphosy Annual Report ,Morphosys Ag Stock Exchange ,News ,Information ,Press Release ,Morphosys ,Key ,Ompletes ,Enrollment ,F ,Hase , ,Study ,Pelabresib ,N ,Myelofibrosis ,Ith ,Topline ,Results ,Xpected ,Y ,End ,F Mor De0006632003 ,